Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Pacira BioSciences, Inc. (PCRX) had Revenue of $177.38M for the most recently reported fiscal quarter, ending 2026-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2026-03-31

Income Statement Financials
Revenue	$177.38M
Net Income	$2.92M
Cost of Goods Sold	$36.41M
Gross Profit	$140.96M
Operating Expenses	$170.47M
Operating Income	$6.90M
Non-Operating Income/Expense	$-1.90M
Pre-Tax Income	$5.00M
Normalized Pre-Tax Income	$5.00M
Income after Taxes	$2.92M
Income from Continuous Operations	$2.92M
Consolidated Net Income/Loss	$2.92M
Normalized Income after Taxes	$2.92M
EBIT	$6.90M
EBITDA	$28.24M
Weighted-Average Shares Outstanding (Basic)	40.46M
Weighted-Average Shares Outstanding (Diluted)	40.91M
Earnings per Share (EPS) (Basic)	$0.07
Earnings per Share (EPS) (Diluted)	$0.07
Balance Sheet Financials
Current Assets	$514.96M
Property, Plant, and Equipment	$136.28M
Long-Term Assets	$693.57M
Total Assets	$1.21B
Current Liabilities	$108.79M
Long-Term Debt	$367.66M
Long-Term Liabilities	$445.85M
Total Liabilities	$554.64M
Common Equity	$653.89M
Tangible Shareholders Equity	$280.89M
Shareholders Equity	$653.89M
Common Shares Outstanding	39.31M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$25.68M
Cash Flow from Investing Activities	$19.44M
Cash Flow from Financial Activities	$-59.40M
Beginning Cash	$158.54M
End Cash	$144.31M
Increase/Decrease in Cash	$-14.24M
Stock-Based Compensation	$13.54M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.73
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.36
Debt to Equity Ratio	0.56
Gross Margin	79.47%
Operating Margin	3.89%
EBIT Margin	3.89%
EBITDA Margin	--
Pre-Tax Profit Margin	2.82%
Profit Margin	1.64%
Free Cash Flow	$22.96M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.15
Inventory Turnover	0.24
Receiveable Turnover	1.41
Days Sales in Receivables	63.75
Return on Equity	0.45%
Return on Tangible Equity	1.04%
Return on Assets	0.24%
Return on Investments	0.29%
Book Value Per Share	$16.63
Free Cash Flow per Share	$0.56
Operating Cash Flow per Share	$0.63

Data from Zacks Investment Research, Inc.